Radotinib (Supect)
Revision as of 00:30, 6 September 2022 by Warner-admin (talk | contribs) (Text replacement - "[[Chronic myelogenous leukemia" to "[[Chronic myeloid leukemia")
Not currently approved in the United States.
Mechanism of action
From the NCI Drug Dictionary: a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib specifically inhibits the Bcr-Abl fusion protein, an abnormal enzyme expressed in Philadelphia chromosome-positive chronic myeloid leukemia (CML) cells. In addition, this agent also inhibits PDGFR thereby blocking PDGFR-mediated signal transduction pathways.
Diseases for which it is used
Also known as
- Code name: IY5511HCl
- Brand name: Supect